199 related articles for article (PubMed ID: 33210064)
1. Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals.
Møller AMJ; Delaisse JM; Olesen JB; Bechmann T; Madsen JS; Søe K
JBMR Plus; 2020 Nov; 4(11):e10412. PubMed ID: 33210064
[TBL] [Abstract][Full Text] [Related]
2. A variability in response of osteoclasts to zoledronic acid is mediated by smoking-associated modification in the DNA methylome.
Tan Q; Møller AMJ; Qiu C; Madsen JS; Shen H; Bechmann T; Delaisse JM; Kristensen BW; Deng HW; Karasik D; Søe K
Clin Epigenetics; 2023 Mar; 15(1):42. PubMed ID: 36915112
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
4. Mevalonates restore zoledronic acid-induced osteoclastogenesis inhibition.
Nagaoka Y; Kajiya H; Ozeki S; Ikebe T; Okabe K
J Dent Res; 2015 Apr; 94(4):594-601. PubMed ID: 25535203
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.
Shibuya I; Takami M; Miyamoto A; Karakawa A; Dezawa A; Nakamura S; Kamijo R
Pathol Oncol Res; 2019 Jan; 25(1):409-419. PubMed ID: 29159783
[TBL] [Abstract][Full Text] [Related]
6. How zoledronic acid improves osteoporosis by acting on osteoclasts.
Wang B; Zhan Y; Yan L; Hao D
Front Pharmacol; 2022; 13():961941. PubMed ID: 36091799
[TBL] [Abstract][Full Text] [Related]
7. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
Mundy GR; Yoneda T; Hiraga T
Semin Oncol; 2001 Apr; 28(2 Suppl 6):35-44. PubMed ID: 11346863
[TBL] [Abstract][Full Text] [Related]
8. Identification of biphenylcarboxylic acid derivatives as a novel class of bone resorption inhibitors.
Van 't Hof RJ; Idris AI; Ridge SA; Dunford J; Greig IR; Ralston SH
J Bone Miner Res; 2004 Oct; 19(10):1651-60. PubMed ID: 15355560
[TBL] [Abstract][Full Text] [Related]
9. Minimally effective concentration of zoledronic acid to suppress osteoclasts
Li P; Zhao Z; Wang L; Jin X; Shen Y; Nan C; Liu H
Exp Ther Med; 2018 Jun; 15(6):5330-5336. PubMed ID: 29904413
[TBL] [Abstract][Full Text] [Related]
10. Aging and menopause reprogram osteoclast precursors for aggressive bone resorption.
Møller AMJ; Delaissé JM; Olesen JB; Madsen JS; Canto LM; Bechmann T; Rogatto SR; Søe K
Bone Res; 2020; 8():27. PubMed ID: 32637185
[TBL] [Abstract][Full Text] [Related]
11. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
[TBL] [Abstract][Full Text] [Related]
12. Effects of zoledronic acid and geranylgeraniol on angiogenic gene expression in primary human osteoclasts.
Zafar S; P Cullinan M; K Drummond B; J Seymour G; E Coates D
J Oral Sci; 2020; 62(1):79-83. PubMed ID: 31996529
[TBL] [Abstract][Full Text] [Related]
13. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts.
Kellinsalmi M; Mönkkönen H; Mönkkönen J; Leskelä HV; Parikka V; Hämäläinen M; Lehenkari P
Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):382-91. PubMed ID: 16364054
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
Jobke B; Milovanovic P; Amling M; Busse B
Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
[TBL] [Abstract][Full Text] [Related]
15. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
[TBL] [Abstract][Full Text] [Related]
16. Bone-site-specific responses to zoledronic acid.
Vermeer J; Renders G; van Duin MA; Jansen I; Bakker LF; Kroon SA; de Vries TJ; Everts V
Oral Dis; 2017 Jan; 23(1):126-133. PubMed ID: 27706930
[TBL] [Abstract][Full Text] [Related]
17. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases.
Schem C; Tower RJ; Kneissl P; Rambow AC; Campbell GM; Desel C; Damm T; Heilmann T; Fuchs S; Zuhayra M; Trauzold A; Glüer CC; Schott S; Tiwari S
J Bone Miner Res; 2017 Mar; 32(3):536-548. PubMed ID: 27714838
[TBL] [Abstract][Full Text] [Related]
19. Osteoclastogenic capacity of peripheral blood mononuclear cells is not different between women with and without osteoporosis.
Koek WNH; van der Eerden BCJ; Alves RDAM; van Driel M; Schreuders-Koedam M; Zillikens MC; van Leeuwen JPTM
Bone; 2017 Feb; 95():108-114. PubMed ID: 27845263
[TBL] [Abstract][Full Text] [Related]
20. Osteoblast-Osteoclast Coculture Amplifies Inhibitory Effects of FG-4592 on Human Osteoclastogenesis and Reduces Bone Resorption.
Hulley PA; Papadimitriou-Olivgeri I; Knowles HJ
JBMR Plus; 2020 Jul; 4(7):e10370. PubMed ID: 32666021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
